A randomized controlled clinical trial to examine effects of intranasal dexmedetomidine, an α2-adrenorecptor agonist, on pain control and agitation in children undergoing BMT.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
101
Normal saline, given intranasally
Fentanyl, nasal transmucosal, 2 micrograms/kilogram
Dexmedetomidine, transmucosal, 1 microgram/kilogram
Children's National Medical Center
Washington D.C., District of Columbia, United States
Incidence of Pain
Pain greater than a zero reported in the Post Anesthesia Care Unit (PACU)
Time frame: up to 24 hours
Length of Stay in PACU
Total time from PACU entry until discharge
Time frame: up to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dexmedetomidine, 2 microgram/kilogram, transmucosal route